By binding to GLP-1 receptors, Ozempic promotes insulin secretion, reduces glucagon production (which lowers blood sugar), and slows down stomach emptying, leading to decreased appetite
Because obviously not every doctor is trained in hormones and endocrine system
Potential Side Effects of GLP-1s Like any drug, GLP-1s arent perfect
What's legal and what changed
How Meal Timing Affects Foods That Increase GLP-1 Levels Naturally How you eat is just as important as what you eat
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
